Abstract. Gastric cancer is the second leading cause of cancer mortality worldwide. Understanding the multistep process of carcinogenesis of gastric cancer is pivotal to develop novel therapeutic strategies. Molecular imaging in preclinical cancer models bridges the gap of laboratory-based experiment and clinical translation. To this end, the human gastric cancer cell line SGC-7901 was established to stably express luciferase and GFP by lentiviral transduction (SGC7901-Luc-GFP). Preclinical models were developed by orthotopic transplantation of SGC-7901-Luc-GFP into the sub-serosal layer of the stomach of immunocompromised mice. Tumor progression and therapeutic responses were dynamically tracked by bioluminescence imaging (BLI). Bioluminescence tomography (BLT) was used to monitor stereoscopic morphological and signal changes during tumor progression. Good correlation between cell number and bio luminescence/ fluorescence intensity was observed (R 2 =0.9983/r 2 =0.9974) in vitro. Tumor progression and therapeutic response could be successfully followed directly by BLI. Importantly, BLT provided a more accurate spatial location and tomographic quantification of the internal lesion. In conclusion, our novel bioluminescence-based preclinical gastric cancer models enable superior, noninvasive monitoring gastric cancer progression and their drug responses. The BLT technique in particular, may have great potential for future oncological studies.
Introduction
Gastric cancer is the second leading cause of cancer mortality worldwide with a 5-year survival rate of 20-30% for the advanced disease (1, 2) . Therefore, understanding the multistep of carcinogenesis of gastric cancer is a pivotal to develop novel therapeutic strategy.
Currently, molecular imaging technology which allows for non-invasive and longitudinal observation has become an invaluable tool for cancer preclinical studies (3, 4) . Bioluminescence imaging (BLI), especially, demonstrates the most desirable combination of high sensitivity and easy handling (5) and is suitable for acquire signal deep in tissue (6) . It has been widely used for monitoring different cancer biological processes [angiogenesis (7, 8) , infinite proliferation and meta stasis (9, 10) , multidrug resistance (11, 12) ] and assessing the efficacy of different therapeutic modalities (13) (14) (15) .
Rodent cancer model is the essential link between laboratory-based experiments and clinical translation of novel therapeutic strategies. Compared with ectopic cancer models, such as subcutaneous, experimental or metastasis models, orthotopic implantation has some unique advantages. Firstly, it preserves the maximum extent of the cancer 'nature' microenvironment (16) (17) (18) . In addition, the orthotopic cancer model reflects a relevant site to assess therapeutic outcomes, avoiding the false-positive drug responses caused by other cancer models (19) . Although the orthotopic gastric cancer model has been employed in previous studies (20) (21) (22) , little attention has been paid to its direct use for in vivo longitudinal monitoring and drug evaluation.
In recent years, the development of new biomedical imaging technology has witnessed discontent with the BLI technique, which only provides 2-dimensional information. Therefore, a more accurate anatomical location is required to describe the cancerous lesion in a whole-body view. Combined with BLT and micro-CT, hybrid bioluminescence tomography (BLT) is able to provide both source localization and distribution inside a living animal, which produces accurate tomographic reconstructions and visualization of the cancer lesion in a 3-dimentional (3D) mode (23, 24) . To the best of our knowledge, few studies have been done on 3D reconstruction of an orthotopic gastric tumor with molecular imaging. In this study, human gastric cancer cell line SGC7901 was established to stably express luciferase and GFP by lentiviral transduction (SGC7901-Luc-GFP). This cell subsequently was used to develop novel preclinical models of gastric cancer. Our model enabled sensitive detection of tumor progression and therapeutic responses by bioluminescence imaging (BLI). In addition, bioluminescent tomography (BLT) can successfully monitor stereoscopic morphological and signal changes during tumor progression.
Real

Materials and methods
Cell culture. Lentivirus packaging cell line HEK-293T and gastric cancer cell line SGC-7901 were preserved in our laboratory and were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 10% fetal calf serum (FCS) (HyClone; Thermo Scientific), 100 U/ml penicillin and 0.1 mg/ml streptomycin. Cells were maintained at 37˚C in an incubation chamber with 5% CO 2 .
Lentivirus production and double-labeled cell line construction.
Lentivirus plasmid pWPT-GFP, pMD2.G, psPAX2 and pLenti-CMV-Puro-LUC were purchased from Addgene (catalog nos. 12255, 12259, 12260 and 17477); lentivirus packaging plasmids Delta 8.9 and VSVG were kindly provided by Professor C. Lois. The day before transduction, 4x10 6 low-passage and healthy 293T cells were seeded in a 10 cm dish. When cells obtained 60-70% confluency, the transduction was done by introducing pLenti-CMV-Puro-LUC, delta 8.9 and VSVG into 293T cells using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions. At 48 h post-transduction, the supernatant was collected, filtered and stored at -80˚C. The day prior to infection, 5x10 5 SGC-7901 cells were plated in the 6-well plate, while lentivirus stocks and polybrene (8 µg/ml; Millipore) were fully mixed in complete growth medium. The plate was then centrifuged at 1200 x g for 90 min at 32˚C. The medium was changed the next day; puromycin (1.0 µg/ml; Sigma) was added at 48 h post-transduction and maintained for ~2 weeks. As for GFP lentivirus packing and transduction, procedures were almost the same as described previously, except for the plasmids we used (pWPT-GFP, pMD2.G, psPAX2). Transduction efficiency was monitored by a converted fluorescence microscope (IX51; Olympus), and fluorescenceactivated cell sorting (FACS; BD Biosciences) was used to collect the GFP-positive cells.
In vitro imaging of SGC7901-Luc-GFP. Different number of cells for SGC7901-Luc-GFP was used in bioluminescence and fluorescence imaging. Before imaging, SGC7901-Luc-GFP cells were placed in a 96-well plate, and a 2-fold serial dilution was made. Then, the culture plate was placed in a light-tight chamber equipped with a halogen light source (IVIS Kinetics; Caliper Life Science). For GFP imaging, the whole image was acquired for a 5 sec exposure with a GFP filter set and excitation wavelength at 465 nm. For bioluminescence imaging, 5 µl D-luciferin (150 µg/ml; Caliper Life Science) was added 1 min prior to imaging, and a bioluminescent signal was then measured for a 180 sec/3 min acquisition. Regions of interest (ROIs) were drawn and light intensity was quantified using Living Image version 4. Animals were anesthetized with ketamine and xylazine, and a 2-3 cm upper left abdominal incision was cautiously made. The stomach was carefully exposed, and 5x10 6 SGC7901-Luc-GFP cells suspended in 50 µl DMEM were orthotopically inoculated into the sub-serosa layer of the stomach wall using 30-G needles (Becton; Dickinson and Company). The microinjection site was pressed with a cotton swab for several minutes in case of cell suspension effusion resulting in peritoneal cavity implantation. The stomach was then prudently returned to the peritoneal cavity, and the abdominal wall and skin were closed with Prolene suture. All of the procedures were done with the aid of a stereomicroscope (SZX7; Olympus).
In vivo bioluminescence imaging and drug response monitoring.
Mice were anesthetized with isofluorane and subsequently received filter-sterilized D-luciferin solution (150 mg/kg body weight) intraperitoneally. The mice were then placed in the chamber with right lateral recumbency. Ten minutes after D-luciferin injection, BLI was implemented for obtaining the peak intensity signal. The bioluminescent intensities of the ROIs were measured and represented as previously described.
Seven days after tumor incubation, the mice were assigned to receive docetaxel (8mg/kg; Taxotere, Sanofi-Aventis) or 0.9% saline treatment once a week. Mouse composition in a different group was kept balanced according to the bioluminescent intensity prior to drug admiration. Drug response was monitored by BLI.
Three-dimensional reconstruction via bioluminescence tomography. Random mouse models from the treated group were imaged to estimate the drug response sensitivity after treatment at an appropriate time point through bioluminescence tomography. In a similar way of bioluminescence imaging, the D-luciferin solution (150 mg/kg body weight) was injected into the mouse peritoneal cavity (i.p.) 10 min prior to bioluminescence tomography, and then the mouse was placed onto the warmed stage inside the light-tight chamber and received continuous exposure under gaseous anesthesia (isoflurane 2%, oxygen 0.3 liters/min) to sustain sedation during imaging. Micro-CT slices of the mouse models were accurately segmented through intraperitoneal Iohexol accumulative contrast enhancement to obtain the anatomical information (25) such as for the heart, lungs, liver, stomach, and kidneys using commercially available software Amira 4.1.1 (Mercury Computer System, Inc.). In this heterogeneous tumor-bearing mouse model, all optical para meters with a 620 nm wavelength (shown in Table I ) were adopted for different organs and tissues. Bioluminescence tomography was quantified in units of total power (nW) inside the living mouse, where the reconstruction algorithm based on the finite element method (FEM) was adopted in our studies of gastric cancer reconstruction in vivo (26, 27) .
Histological studies. Mice were sacrificed at the end of the experiment. The primary stomach lesion was excised. The tissues were fixed in formalin, embedded in paraffin and contiguous sections (4 µm) were obtained for hematoxylin and eosin H&E analysis. Frozen (8 µm) sections were also prepared at -20˚C to confirm GFP existence (CM1900; Leica), and fluorescent images were collected via fluorescent microscope (BX51; Olympus). The slices were analyzed by two independent pathologists at our laboratory.
Statistical analysis. Data are expressed as the mean ± standard deviation (SD). A Student's t-test was used to assess the P-value. Analysis of variance (ANOVA) for repeated measures was implemented to analyze drug efficacy. Regression plots were used to describe the correlation. PASW Statistics 18.0 (SPSS Inc., IBM Corp.) was used for statistical analysis. Differences between groups were considered as statistically significant at P<0.05.
Results
Characteristics of the transformed gastric cell line SGC7901-Luc-GFP. The stable expression of Luciferase and GFP in the gastric cancer cell line is a prerequisite for intensive research with an advanced molecular imaging approach. After being sequentially infected by luciferase and GFP contained lentivirus, the gastric cell line SGC7901-Luc-GFP was developed. To determine whether or not the cell characteristics were influenced by the virus infection process, we compared cell proliferation and morphological differences between the transformed clones and their correspondent parental strains. No obvious changes were observed in the in vitro growth pattern; SGC7901-Luc-GFP shared a similar morphological appearance as its parental cells with 90% GFP positive cells (data not shown). To compare the photons generating the ability between transformed and parental cells, we treated both kinds of cells with substrate D-luciferin. The subsequent results showed a steady growth in bioluminescent activity accompanied by an increasing cell number for SGC7901-Luc-GFP; however, no bioluminescence was detected in parental SGC7901 despite a cell number increase (data not shown). Furthermore, we serially diluted the cells and assessed the accuracy of BLI as well as fluorescent imaging as indicators of cell number. Correlation analysis revealed a linear relationship between bioluminescent intensity and cell number (R 2 =0.9983) with a minimum detection of 375 cells per well ( Fig. 1A and B) . As for GFP, a similar trend was also observed (r 2 = 0.9974), but due to the auto-fluorescence, GFP had high signal/noise ratio making it ineffectual in quantifying a small number of cells (Fig. 1C and D) .
Mouse orthotopic model of human gastric cancer. Under the standard surgical procedures, 5x10
6 SGC7901-Luc-GFP cells were injected into the sub-serosa layer of the stomach wall ( Fig. 2A ). There were no complications recorded during the entire operation process and all mice recovered uneventfully from anesthesia. In order to confirm successful implantation, two mice were sacrificed 12 days later. Postmortem examination showed that both mice had developed a stomach tumor on the gastric surface (Fig. 2B) . H&E staining showed that SGC7901-Luc-GFP cells were extensively implanted in the stomach wall with a poorly differentiated and highly mitotic phenotype. Frozen section fluorescent images showed the GFP tumor position in sharp contrast to the normal epithelium ( Fig. 2C and D) .
Tumor progression and regression monitored by in vivo bioluminescence imaging.
In order to explore whether or not our modified cancer cell line could track tumor progression and regression after treatment in vivo, we recorded the dynamic changes in light intensity for each mouse using the bioluminescence imaging system. A bioluminescent signal was detected 2 days after incubation, and signal distribution was mainly focused on the stomach region. On day 7, mice were assigned to receive docetaxel treatment (8 mg/kg) or vehicle (0.9% saline) via tail vein injection weekly. The signal existed through the entire observation period both in the control and treatment group (Fig. 3A) . On day 16, additional signals were recorded beside the primary signal in 2 mice, indicating probable local metastasis; subsequent GFP imaging and H&E analysis confirmed our assumptions (Fig. 3B) . Continuous data revealed an exponential increase in bioluminescent activity that was correlated with tumor progression (R 2 =0.986, Fig. 4A ). Further repeated measurement analysis showed statistical significance between the treatment and control group. However, we noted that docetaxel alone could not eradicate the tumor (P<0.05, Fig. 4B ). At the end of the experiment (day 27), all of the mice were cachexia and inactive. The tumors were resected and weighed after the mice were sacrificed. We then found a good linear correlation between tumor weight and bioluminescent activity (R 2 =0.9795, Fig. 4C ). Moreover, docetaxel treatment delayed tumor growth compared with the saline control group (Fig. 4D) .
Three-dimensional reconstruction of gastric cancer. Through our previously described accumulative contrast enhancement method, good contrast for different organs in the mice was achieved. The outlines of various organs including the heart, lungs, liver, stomach and tumors were carefully segmented in every micro-CT slice. The low background for the bio luminescent signals provided substantially greater sensitivity. Meanwhile, our original optical data showed a strong signal and high signal-to-noise ratio (Fig. 5A) . The restructured image for micro-CT distinctly displayed a stereoscopic shape of the stomach with the tumor. The tomographic reconstruction of the light resource was also ideally co-registered. On day 2, the signal located in the greater curvature of the stomach was consistent with the injection site; on day 21, the light distribution of the same source was mainly focused on the tumor lesion. The total power of BLT reconstruction was 30.4 and 482.1 nW on day 2 and 21, respectively. Moreover, our morphological reconstruction of the affected stomach was similar to the autopsy observation (Fig. 5B) .
Discussion
In this study, we developed a stable expression Firefly luciferase and GFP gastric cancer cell line, SGC7901-Luc-GFP. BLI exhibited superior sensitivity and unsurpassed signal/ noise ratios in in vitro and in vivo imaging, which is consistent with previous studies (28, 29) . We also found a robust correlation between tumor weight and bioluminescence activities. In addition, our transformed cell expressed GFP at a high level, which facilitates postmortem observation since no oxygen or ATP is needed for imaging. Thus, it provides a more accurate assessment of tumor spread. In our research, probable metastatic tissue was resected and confirmed by ex vivo GFP imaging.
The preclinical animal cancer model is the most informative and effective platform to obtain relevant clinical data and evaluate anticancer therapeutics. Previous studies have clearly showed that agent evaluation or a screen carried on an ectopic model must be followed up by relevant orthotopic models (17) . Under the clinical identical microenvironment, tumors were modulated by cellular molecules released by host cells (30) . In the present study, transformed cells were planted within the orthotopic environment to guarantee, to the maximum extent, that tumor evaluation and potential metastasis in research were the most precise representations of what actually happens in human cancer. It is acknowledged that only a small amount of cells could flee from the primary site and eventually metastasize. The properties of metastatic cells vary considerably from those at the primary site (31) (32) (33) . We incidentally recorded spontaneous metastasis on day 16. This orthotopic model was obviously superior to experimental metastasis models.
In the field of in vivo gastric cancer research, BLI technology has several noticeable advantages over traditional methods as summarized below. Firstly, as a non-invasive imaging technique, BLI successfully enables data collection from serial images from the identical animal, which avoids the unnecessary usage of large quantities of animals at different time intervals in cancer studies. Secondly, BLI offers a relative assessment of treatment efficacy compared with other detection means, since it only represents the metabolically active tumor cells rather than volumetric measurement of the tumor mass (9) . Thirdly, BLI can serve as an indicator of successful implantation of tumor cells. This indicative feature of BLI rules out some faulty responses of the drug which are possibly due to unsuccessful implantation of the xenograft. It greatly benefits efficacy evaluation of the drug for those cancers that cannot be directly detected or measured, such as gastric cancer. In this current research, successful incubation of tumor cells was immediately observed with in vivo imaging of the mice. The outcome of docetaxel treatment was tracked by BLI. Furthermore, the BLI technique helped to eliminate statistical variations, thus the mouse composition in a different group was kept balanced according to the bioluminescence intensity before drug administration.
Commercially available BLI only collects the tumor signal in a surface-weighted manner on a two-dimensional plane (13, 34) , which means a weaker source near the surface would have identical light intensity with a stronger source in deep tissue (35) . Therefore, we tried to monitor the progression of gastric tumors by home-developed BLT system for the first time. BLT could partially overcome this limitation and improve data accuracy (36) . Moreover, it conveys information of the anatomical location as well as the bioluminescence signal of the tumor in a stereoscopic view. In our previous studies, BLT was able to reconstruct three-dimensional bioluminescence distribution and provide accurate quantification of the source signal on the basis of appropriate reconstruction algorithm combination of the micro-CT guide (27, (36) (37) (38) (39) (40) (41) . In this study, we utilized BLT to reconstruct morphological appearance and quantify the signal intensity on day 2 and day 21, respectively. BLT quantitative results were more favorable than BLI results since they were competent in magnifying and improving the results shown by BLI, which was more rational for 3D space distribution integration of tumor signals. In addition, the reconstruction appearance of the affected stomach was quite similar to the post-mortem examination results. Collectively, BLT technique provides new alternative solution for future gastric cancer studies.
Nevertheless, this study has three major limitations. Firstly, our cancer model was developed on immunoincompetent mice, which determines that it should be cautiously generalized when applied to immunoregulation agents. Secondly, the post-processing of semi-automatic segmentation used in the study is relatively labor-intensive and time-consuming, which indicates that our BLT data are not sufficient. Therefore, a more manageable and convenient post-processing approach for data collection is expected in further relevant studies. Another limitation addresses BLT reconstruction signal disturbance as tetrahedral shape, which was possibly caused by the finite dissection of the tetrahedral elements. Some tetrahedrons which represent the bioluminescent intensity are discontinuous and isolated in most reconstructed mice. As a result, some intensive studies on this issue are strongly recommended.
The current study developed novel bioluminescencebased preclinical gastric cancer models which enable superior, noninvasive gastric cancer monitoring. As the first group to employ a novel BLT in gastric cancer, we demonstrated that BLT provided more comprehensive information of the cancerous lesion. The implementation of the opticalimaging-based approach may open new avenues for drug evaluations and preclinical oncological investigations in gastric cancer.
